Printer Friendly

LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING

 LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT
 OF BUSINESS DEVELOPMENT AND LICENSING
 LA JOLLA, Calif., Sept. 23 /PRNewswire/ -- LIDAK Pharmaceuticals (NASDAQ: LDAKA) today announced it has hired Timothy R. Russell as vice president of business development and licensing. In this position, Russell will be responsible for all business development and licensing activities including strategic planning and technology in-licensing and out-licensing.
 Russell, 50, brings more than 20 years of pharmaceutical industry experience to LIDAK. He is currently president of Carlsson- Rensselaer Corp. (CR Associates), a healthcare consulting company specializing in technology exchange, licensing and product development. He also serves as a director of Barton & Pittinos Inc., a marketing communications agency, and Scandipharm Inc., a development-stage pharmaceutical company.
 Before forming CR Associates in 1990, Russell served as a member of the board (1983-1990) and vice president, corporate relations (1986-1990) of McNeil Pharmaceutical, a subsidiary of Johnson & Johnson. At McNeil, Russell also served as vice president, business development (1983-1986); executive director, new products (1981-1983); executive director, planning and corporate development (1977-1981); and director of marketing information (1975-1977).
 Prior to joining McNeil in 1975, Russell was employed at Merck and Co., where he held positions as assistant to the president, Merck, Sharp & Dohme Research Laboratories (MSDRL), manager of operations improvement, MSDRL and market research analyst, Merck, Sharp & Dohme.
 According to David H. Katz, LIDAK's president and chief executive officer, Russell is an outstanding addition to LIDAK's management team. "Tim brings a wealth of experience in strategic planning, technology assessment and deal-making to LIDAK which we are certain will be very beneficial to the company," said Katz.
 Russell holds a bachelor's degree in engineering from Rensselaer Polytechnic Institute and a master's degree in business administration from the Wharton School of the University of Pennsylvania.
 LIDAK Pharmaceuticals is attempting to develop pharmaceutical products for the healthcare industry. The company is focusing its efforts on the commercialization of LIDAKOL(TM) as a treatment for herpes and other indications. In addition, it is developing Large Multivalent Immunogen technology as potential new therapies for cancer and viral diseases, and Free Fatty Acid technology as a possible clinical diagnostic assay for the prediction and monitoring of cancer and diabetes. The company is also utilizing surrogate human immune system reconstituted mice technology for evaluating new potential anti-AIDS drugs and potential new diagnostic and treatment approaches to cancer.
 -0- 9/23/92
 /CONTACT: Michael H. Lorber, VP and CFO of LIDAK Pharmaceuticals, 619-558-0364/
 (LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: PER


LS-AL -- LA002 -- 2490 09/23/92 09:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 23, 1992
Words:418
Previous Article:AGENCY RENT-A-CAR, INC. REPORTS REVENUE UP 21 PERCENT
Next Article:J.D. POWER AND ASSOCIATES HONORS CHEVROLET
Topics:


Related Articles
LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
LIDAK PHARMACEUTICALS ISSUES STATEMENT ON RESIGNATION OF DONALD E. MOSLER
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN
LIDAK PHARMACEUTICALS APPOINTS NEW VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS COMPLETES STAFFING OF ITS CLINICAL DEVELOPMENT ADVISORY PANEL WITH ADDITION OF GALLO
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
LIDAK Pharmaceuticals Adds New Vice President and Reports Drug Development Highlights at Annual Meeting
LIDAK Pharmaceuticals Appoints Susan Yeagley Sullivan As New Chief Financial Officer

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters